Organon & Co [OGN] stock is trading at $7.18, up 1.27%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The OGN shares have gain 4.97% over the last week, with a monthly amount drifted -4.39%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Organon & Co [NYSE: OGN] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Underweight rating and assigned the stock a price target of $7.50. Previously, Piper Sandler downgraded its rating to Underweight on October 27, 2025, and kept the price target unchanged to $5. On May 02, 2025, downgrade downgraded it’s rating to In-line. JP Morgan downgraded its rating to a Underweight and increased its price target to $20 on September 06, 2024. Goldman downgraded its rating to a Neutral and reduced its price target to $16 on November 03, 2023. Barclays started tracking with an Overweight rating for this stock on September 21, 2023, and assigned it a price target of $28. In a note dated March 16, 2023, Raymond James initiated an Outperform rating and provided a target price of $33 on this stock.
Organon & Co [OGN] stock has fluctuated between $6.18 and $17.23 over the past year. Currently, Wall Street analysts expect the stock to reach $6.25 within the next 12 months. Organon & Co [NYSE: OGN] shares were valued at $7.18 at the most recent close of the market. An investor can expect a potential drop of -12.95% based on the average OGN price forecast.
Analyzing the OGN fundamentals
Organon & Co [NYSE:OGN] reported sales of 6.30B for the trailing twelve months, which represents a growth of 1.26%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.76 and Total Capital is 0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 9.74.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.06 points at the first support level, and at 6.93 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.26, and for the 2nd resistance point, it is at 7.33.
Ratios To Look Out For
For context, Organon & Co’s Current Ratio is 1.75. Also, the Quick Ratio is 1.20, while the Cash Ratio stands at 0.0. Considering the valuation of this stock, the price to sales ratio is 0.30, the price to book ratio is 2.06 and price to earnings (TTM) ratio is 3.73.
Transactions by insiders
Recent insider trading involved COX CARRIE SMITH, Executive Chair, that happened on Nov 12 ’25 when 65400.0 shares were purchased. Director, COX CARRIE SMITH completed a deal on May 14 ’25 to buy 12469.0 shares. Meanwhile, Chief Human Resources Officer Falcione Aaron bought 5500.0 shares on May 07 ’25.
